Literature DB >> 11697756

Pharmacokinetics of norelgestromin and ethinyl estradiol from two consecutive contraceptive patches.

L S Abrams1, D M Skee, F A Wong, N J Anderson, P T Leese.   

Abstract

The primary objective of this open-label study was to determine the pharmacokinetics of norelgestromin (NGMN) and ethinyl estradiol (EE)following two consecutive applications of a contraceptive patch (ORTHO EVRA/EVRA). Twelve healthy women wore the first patch on their abdomen for 7 days and, after removal at 168 hours (day 7), wore a second patch for 10 days (i.e., 3 days beyond the intended 7-day wear period). Blood samples were collected before and at various times up to 456 hours (day 19) after application of the first patch for analysis of NGMN and EE. Mean serum concentrations of NGMN and EE remained within the reference ranges, 0.6 to 1.2 ng/ml and 25 to 75 pg/ml, respectively, during the entire 7-day wear period after application of the first patch and for 10 days after application of the second patch; reference ranges are based on studies with ORTHO-CYCLEN/ Cilest. No patch detached spontaneously. No subject discontinued or experienced a serious adverse event.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11697756     DOI: 10.1177/00912700122012788

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  2 in total

1.  Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites.

Authors:  Larry S Abrams; Donna M Skee; Jaya Natarajan; Frankie A Wong; Gary D Anderson
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

2.  Metabolic effects of the contraceptive skin patch and subdermal contraceptive implant in Mexican women: a prospective study.

Authors:  Jesus Hernandez-Juarez; Ethel A Garcia-Latorre; Manuel Moreno-Hernandez; Jose Fernando Moran-Perez; Miguel Angel Rodriguez-Escobedo; Gerardo Cogque-Hernandez; Rubén Julián-Nacer; Xochitl Hernandez-Giron; Rosalia Palafox-Gomez; Irma Isordia-Salas; Abraham Majluf-Cruz
Journal:  Reprod Health       Date:  2014-04-26       Impact factor: 3.223

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.